Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | February 2012 |
| End Date: | April 2015 |
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)
This study will further analyze the use of ceftaroline for CABP and compare its potential to
eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of
ceftaroline compared to levofloxacin may be further highlighted from this investigation.
eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of
ceftaroline compared to levofloxacin may be further highlighted from this investigation.
Inclusion Criteria:
- non-pregnant adults (≥ 18 years old) with suspected CABP admitted to the hospital for
parenteral antibiotic therapy.
- All patients will have a creatinine clearance (CrCl) >50 ml/min.
Exclusion Criteria:
- pregnant or nursing patients,
- allergy to penicillin/cephalosporin antibiotics,
- allergy to fluoroquinolones,
- renal or hepatic failure, or have received an antimicrobial in past 96h.
- Patients who require antibiotics other than the study drugs will also be excluded.
We found this trial at
1
site
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
Click here to add this to my saved trials
